Comparing Dexcom G7 continuous glucose monitoring versus fingerstick point-of-care testing for hospitalized and recently discharged people with type 1 diabetes.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Hospitalized adults with poorly controlled type 1 diabetes who expect to stay more than three days will be assigned to either real-time Dexcom G7 continuous glucose monitoring or standard point-of-care capillary glucose testing to guide insulin therapy. The study will track percent time-in-range (70–180 mg/dL) and the frequency of hypoglycemia during the inpatient stay and shortly after discharge. Key exclusions include ICU admission, prior home CGM use, pregnancy, MRI requirement during admission, systemic immunosuppression, and type 2 diabetes. Results aim to determine whether CGM provides a clearer glycemic picture and fewer low or high glucose events than routine fingerstick testing in this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Known history of T1D treated with insulin therapy (human regular or rapid-acting analogs or ultra-rapid analogs \[lispro, aspart, glulisine, fast-acting insulin aspart, insulin lispro\]), intermediate-acting (NPH and premixed formulations) or long-acting basal (glargine, detemir, degludec) formulations.
* Admission diagnosis of T1D with poorly controlled diabetes (blood glucose \> 180 mg/dl, HbA1c \> 7%), including diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS).
* Expected length of hospital stay \> three days at the time of randomization

Exclusion Criteria:

* Patients admitted to the ICU
* Subjects using CGM technology before admission
* Subjects with type 2 diabetes
* Treatment with systemic immunosuppressive agents
* Cystic fibrosis
* Prisoners
* Patients expected to require MRI procedures during hospitalization.
* Female subjects who are pregnant or breastfeeding at enrollment into the study.
* Subjects not willing to wear a CGM device
* Subjects with clinically relevant hepatic disease (diagnosed liver cirrhosis and portal hypertension) and end-stage kidney disease (eGFR\< 30 ml/min), or terminal illness.
* Subjects with a history of cognitive impairment, dementia, or mental condition rendering the subject unable to understand the nature and consequences of the study

Where it's running

• Grady Memorial Hospital
  Atlanta, Georgia, United States Recruiting

Study contacts

• Principal investigator: Guillermo Umpierrez, MD — Emory University
• Study coordinator: Guillermo Umpierrez, MD
• Email: geumpie@emory.edu
• Phone: 404-778-1665

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Semaglutide on body composition in adults with type 1 diabetes and overweight/obesity

  This study tests whether weekly semaglutide changes body composition in adults with type 1 diabetes who are overweight or obese, compared with a placebo over 24 weeks.

  Recruiting Phase 2/3 McGill University Health Centre/Research Institute of the McGill University Health Centre · Montreal, Quebec · NCT07891156

• Next Generation Extended Wear Sensors in Type 1 and Type 2 Diabetes

  This study tests a new extended wear sensor and algorithm in people with type 1 or type 2 diabetes to see how well it works across adults and children.

  Recruiting at 11 sites Medtronic MiniMed, Inc. · Chula Vista, California and 17 other locations · NCT07864168

• CGM-guided carb awareness education for adults with Type 1 diabetes

  This study tests whether teaching mealtime insulin dosing using CGM data helps adults with Type 1 diabetes who don’t usually count carbs.

  Recruiting University of California, Los Angeles · Los Angeles, California · NCT07807280

• Safety and effectiveness of GLP-1 receptor agonists and SGLT inhibitors added to insulin in adults with type 1 diabetes

  This registry will see if adding GLP-1RA or SGLTi therapies to insulin helps adults with type 1 diabetes over one year.

  Recruiting at 17 sites Indiana University · Newport Beach, California and 16 other locations · NCT07676565

• Think-Find-Solve activities for insulin self-management in children with type 1 diabetes

  A behavior-change activity book is tested with children aged 8–12 with type 1 diabetes and their parents to see if it improves daily insulin self-management.

  Recruiting Marmara University · Istanbul · NCT07670572

• Near-sensor insulin delivery with CGM in people with type 1 diabetes

  A small early-feasibility study tests a dual-port insulin patch pump that includes a CGM sensor to see if delivering insulin near the sensor affects glucose readings and whether an automated control algorithm can manage glucose.

  Recruiting Early Phase 1 ClinSurge Research · Toronto, Ontario · NCT07655076

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.